文献速递垂体与肾上腺疾病

侵袭性垂体瘤与垂体癌:从病理到治疗

Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

本文综述侵袭性垂体瘤(APT)与垂体癌(PC)的异质性、病理与遗传标志及治疗策略。PC中Ki67≥10%和p53广泛表达更常见,TP53与ATRX突变最常见。替莫唑胺为推荐一线化疗,缓解率约40%;免疫检查点抑制剂作为PC二线治疗,PD-1单药与双药疗效无 superiority 证据。

要点

  • PC中Ki67≥10%和p53广泛表达较APT更常见,TP53与ATRX突变最常见。
  • 替莫唑胺为推荐一线化疗,缓解率约40%。
  • 免疫检查点抑制剂为PC二线治疗,PD-1双药对比单药无更优证据。

核心结论

  • APT与PC在临床表现、增殖标志物、临床病程和治疗反应上具有异质性,约半数在首次看似良性表现多年后才呈侵袭性病程。
  • APT/PC管理具有挑战性,应在专家团队内结合临床与病理发现、年龄及患者一般状况进行讨论。
  • 鉴于APT/PC罕见,新疗法最好在共享的标准化方案中评估;指导治疗决策的预后与预测标志物有待研究。

研究设计与样本

  • 本文为综述,检索范围未在原文摘要中报告。

主要发现

  • APT与PC共享若干特性,但Ki67指数≥10%和p53广泛表达在PC中更普遍。
  • TP53和ATRX突变是最常见的遗传改变,其检测可能有助于早期识别侵袭性。
  • 替莫唑胺缓解率约40%;贝伐珠单抗在少数患者中达部分缓解(PR);酪氨酸激酶抑制剂和依维莫司通常无效;肽受体放射性核素治疗效应也有限。
  • 免疫检查点抑制剂已成为PC二线治疗,目前无双药治疗优于PD-1阻断剂单药的证据。

关键数值与推荐

  • 替莫唑胺为推荐的一线化疗,缓解率约40%。
  • 免疫检查点抑制剂作为PC二线治疗,目前无证据表明双药治疗优于PD-1阻断剂单药。

临床怎么用

  • APT/PC的管理应在专家团队内讨论,综合考虑临床与病理发现、年龄及患者一般状况。
  • 鉴于APT/PC罕见,新疗法最好在共享的标准化方案中评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with regard to clinical presentation, proliferative markers, clinical course, and response to therapy. Half of them show an aggressive course only many years after the first apparently benign presentation. APTs and PCs share several properties, but a Ki67 index greater than or equal to 10% and extensive p53 expression are more prevalent in PCs. Mutations in TP53 and ATRX are the most common genetic alterations; their detection might be of value for early identification of aggressiveness. Treatment requires a multimodal approach including surgery, radiotherapy, and drugs. Temozolomide is the recommended first-line chemotherapy, with response rates of about 40%. Immune checkpoint inhibitors have emerged as second-line treatment in PCs, with currently no evidence for a superior effect of dual therapy compared to monotherapy with PD-1 blockers. Bevacizumab has resulted in partial response (PR) in few patients; tyrosine kinase inhibitors and everolimus have generally not been useful. The effect of peptide receptor radionuclide therapy is limited as well. Management of APT/PC is challenging and should be discussed within an expert team with consideration of clinical and pathological findings, age, and general condition of the patient. Considering that APT/PCs are rare, new therapies should preferably be evaluated in shared standardized protocols. Prognostic and predictive markers to guide treatment decisions are needed and are the scope of ongoing research.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Burman P, Casar-Borota O, Perez-Rivas LG, et al. Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment. J Clin Endocrinol Metab. 2023. PMID: 36856733. doi:10.1210/clinem/dgad098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。